Company Profile
HBL - Hadasit Bio-Holdings provides the medical and biotechnology research and development activities in Israel. The company's portfolios are developing novel protein drugs for cancer immunotherapy and stem cell-based therapies for the treatment of eye diseases. It also involved in the development of treatments for cancer and autoimmune diseases
Cell therapy in autoimmune and inflammatory conditions for the treatment of graft-versus-host disease (GVHD) in bone marrow transplants, treatment of sepsis as well as for coronavirus patients in severe conditions, combination therapy with cancer drugs as well as other inflammatory and autoimmune diseases. HBL - Hadasit Bio-Holdings Ltd was incorporated in 2005 and is based in Jerusalem, Israel.